Tevogen Bio (TVGN) Competitors $0.91 -0.01 (-0.88%) As of 11:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVGN vs. DAWN, PROK, DNTH, GHRS, MRVI, TBPH, UPXI, MGTX, ABUS, and KALVShould you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Day One Biopharmaceuticals (DAWN), ProKidney (PROK), Dianthus Therapeutics (DNTH), GH Research (GHRS), Maravai LifeSciences (MRVI), Theravance Biopharma (TBPH), Upexi (UPXI), MeiraGTx (MGTX), Arbutus Biopharma (ABUS), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. Tevogen Bio vs. Its Competitors Day One Biopharmaceuticals ProKidney Dianthus Therapeutics GH Research Maravai LifeSciences Theravance Biopharma Upexi MeiraGTx Arbutus Biopharma KalVista Pharmaceuticals Tevogen Bio (NASDAQ:TVGN) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends. Which has stronger earnings and valuation, TVGN or DAWN? Tevogen Bio has higher earnings, but lower revenue than Day One Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTevogen BioN/AN/A-$13.73MN/AN/ADay One Biopharmaceuticals$131.16M5.36-$95.50M-$0.95-7.23 Which has more volatility and risk, TVGN or DAWN? Tevogen Bio has a beta of -0.77, suggesting that its share price is 177% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.26, suggesting that its share price is 226% less volatile than the S&P 500. Does the media favor TVGN or DAWN? In the previous week, Tevogen Bio had 3 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 11 mentions for Tevogen Bio and 8 mentions for Day One Biopharmaceuticals. Tevogen Bio's average media sentiment score of 0.65 beat Day One Biopharmaceuticals' score of 0.45 indicating that Tevogen Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 1 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Day One Biopharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is TVGN or DAWN more profitable? Tevogen Bio has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -50.63%. Tevogen Bio's return on equity of 0.00% beat Day One Biopharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tevogen BioN/A N/A -775.49% Day One Biopharmaceuticals -50.63%-19.01%-16.99% Do analysts recommend TVGN or DAWN? Tevogen Bio currently has a consensus price target of $10.00, suggesting a potential upside of 997.69%. Day One Biopharmaceuticals has a consensus price target of $25.29, suggesting a potential upside of 268.33%. Given Tevogen Bio's higher possible upside, equities research analysts clearly believe Tevogen Bio is more favorable than Day One Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Do institutionals and insiders hold more shares of TVGN or DAWN? 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. 73.2% of Tevogen Bio shares are owned by insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryTevogen Bio beats Day One Biopharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Tevogen Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVGN vs. The Competition Export to ExcelMetricTevogen BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$167.52M$3.11B$5.76B$9.59BDividend YieldN/A2.23%4.53%4.07%P/E RatioN/A20.4730.4425.11Price / SalesN/A235.16391.4087.03Price / CashN/A42.3737.0358.50Price / Book-9.117.868.886.18Net Income-$13.73M-$54.72M$3.26B$265.56M7 Day Performance-7.04%0.74%0.47%-1.43%1 Month Performance-20.78%4.90%3.66%-0.98%1 Year Performance47.41%8.47%27.89%18.83% Tevogen Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVGNTevogen Bio3.9389 of 5 stars$0.91-0.9%$10.00+997.7%+48.9%$167.52MN/A0.003Earnings ReportAnalyst ForecastDAWNDay One Biopharmaceuticals2.4559 of 5 stars$6.81+0.9%$25.33+272.0%-51.0%$691.42M$131.16M-7.1760News CoverageAnalyst ForecastInsider TradePROKProKidney3.7257 of 5 stars$2.54+7.6%$6.25+146.1%-2.6%$690.77M$80K-4.463News CoverageAnalyst DowngradeShort Interest ↓DNTHDianthus Therapeutics1.0572 of 5 stars$20.96+1.1%$53.00+152.9%-19.2%$674.66M$4.85M-6.4580Analyst ForecastHigh Trading VolumeGHRSGH Research2.9953 of 5 stars$12.67-0.9%$32.00+152.6%+12.1%$665.44MN/A-17.1210Positive NewsMRVIMaravai LifeSciences3.874 of 5 stars$2.57-1.5%$5.75+123.7%-72.6%$664.66M$259.18M-1.89610Options VolumeTBPHTheravance Biopharma2.1986 of 5 stars$13.61+3.5%$21.33+56.7%+62.9%$662.25M$77.21M56.71110High Trading VolumeUPXIUpexi2.7431 of 5 stars$6.92-5.9%$15.50+124.0%+89.4%$656.81M$26M0.00130MGTXMeiraGTx4.4697 of 5 stars$7.97-2.4%$24.00+201.1%+79.6%$656.59M$33.28M-3.91300Earnings ReportABUSArbutus Biopharma2.8711 of 5 stars$3.38+0.3%$5.50+62.7%-8.9%$647.94M$15.42M-11.6690KALVKalVista Pharmaceuticals3.9956 of 5 stars$13.34+3.6%$26.29+97.0%+3.2%$643.41MN/A-3.62100 Related Companies and Tools Related Companies Day One Biopharmaceuticals Competitors ProKidney Competitors Dianthus Therapeutics Competitors GH Research Competitors Maravai LifeSciences Competitors Theravance Biopharma Competitors Upexi Competitors MeiraGTx Competitors Arbutus Biopharma Competitors KalVista Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVGN) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access